NDC 72960-112-06
This exact product or package identity exists in FDA auxiliary data but is not present in the current primary NDC product table. The package identity is preserved; status rows are reported source observations, not medical conclusions.
- Requested NDC
- 72960-112-06
- Product root
- 72960-112
- Identity scope
- Package
- Primary current NDC product row
- Not present
NDC auxiliary status#
These records are reproduced from FDA’s unfinished, excluded, and compounder listings. They describe what appeared in the source files; a missing record does not establish a regulatory status. View all current auxiliary records, including entries without an NDC. · View the auxiliary file history.
| Dataset | Scope | Product NDC | Package NDC | Code | Status | Reporting period | Source date |
|---|---|---|---|---|---|---|---|
| excluded package | package | 72960-112 | 72960-112-06 | D | Discontinued by firm | 2026-08-07 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| DAXXIFY | BOTULINUM TOXIN TYPE A | Revance Therapeutics, Inc. | 3aaa6e14-a3f7-4fb2-b9f9-d3a9c3ae1f74 | 2026-01-07 | Boxed warning, Warnings, Adverse reactions | 72960-112-06 72960-112 72960011206 |